학술논문
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
Document Type
Article
Author
Source
In: European Journal of Cancer . (European Journal of Cancer, November 2021, 158:72-84)
Subject
Language
English
ISSN
18790852
09598049
09598049